Donor Lymphocyte Infusions after Allogeneic Transplantation: A Single Center Experience
Allogeneic hematopoietic cell transplantation (AHCT) represents the only curative therapy for many haematological malignancies. The graft-versus-leukemia effect (GVL), driven by donor Tcells plays a major role in its curative potential. This effect is sometimes very evident when AML and MDS relapses post AHCT are treated with donor lymphocyte infusions (DLI), in which lymphocytes from the original stem cell donor are infused, to augment an anti-tumor immune response or ensure that the donor stem cells remain engrafted, after the transplant.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Fouad Kerbage, Riwa Sakr, Valerie Lapierre, Kamelia Alexandrova, Tereza Coman, Severine Leroux, Nolwenn Lucas, Sylvain Pilorge, Eric Solary, Jean-henri Bourhis, Cristina Castilla-Llorente Tags: Review Article Source Type: research
More News: Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants